Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Icagen/McNeil’s ICA-17043 Is Lead Candidate To Be Second Sickle Cell Drug On Market

This article was originally published in The Pink Sheet Daily

Executive Summary

The compound is poised to begin Phase III; J&J subsidiary McNeil entered a U.S. co-development and commercialization partnership with innovator Icagen for the oral once-daily chronic treatment in June. The orphan drug has fast-track status at FDA.

You may also be interested in...



J&J Terminates Icagen Deal For Senicapoc

Icagen says it will decide whether to continue development of the drug in sickle cell anemia by this fall.

J&J Terminates Icagen Deal For Senicapoc

Icagen says it will decide whether to continue development of the drug in sickle cell anemia by this fall.

Icagen/J&J Sickle Cell Disease Treatment Hits Phase III Snag

An independent data monitoring committee recommends Phase III enrollment continue for ICA-17043, but only for patients on concurrent hydroxyurea therapy.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel